Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01479283 · ClinicalTrials.gov registry record · Phase 3
Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY)
A Phase 3 study, sponsored by McMaster University.
- Completed
- Registry status
- Phase 3
- Development phase
- 602
- Enrollment target
NCT01479283: Completed Phase 3 study, sponsored by McMaster University.
NCT01479283 is a Phase 3 study that has completed, run by McMaster University. The registered enrollment target is 602 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01479283, a Phase 3 study, has completed, sponsored by McMaster University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 602 participants
- Enrollment target
Study Summary
The Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) trial is the first ever international multi-center randomized controlled trial in bone cancer surgery. In order to avoid amputation for bone cancer in the leg, complex limb-saving operations are performed. However, infections with devastating complications following surgery are common. Surgeons from across the world will randomize patients to receive either short- or long-duration antibiotic regimens after surgery with the goal of identifying the best regimen to reduce these infections.
Primary Outcome
the development of a surgical site infection according to the criteria established by the Center for Disease Control (CDC)
Interventions
- DRUG 24-Hour Prophylactic Cefazolin* Antibiotic Regimen
- DRUG 5-Days Prophylactic Cefazolin* Antibiotic Regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 602 participants |
| Start Date | 2013-01 |
| Est. Completion | 2021-03 |
| Phase | Phase 3 |
What the finished NCT01479283 record still lists
NCT01479283 is an interventional study that assigns participants to a tested intervention. The registered 602 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% lower).
The record links to 0 conditions, and to 2 interventions - of which 24-Hour Prophylactic Cefazolin* Antibiotic Regimen is the first listed.
NCT01479283 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01479283 about?
NCT01479283 is a clinical study titled "Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY)". The Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) trial is the first ever international multi-center randomized controlled trial in bone cancer surgery. In order to avoid amputation for bone cancer in the leg, complex limb-saving operations are performed. However, infections with devast...
What is the current status of trial NCT01479283?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 602 participants. The study started on 2013-01. Estimated completion is 2021-03.
What interventions are being tested in trial NCT01479283?
The interventions under investigation include: 24-Hour Prophylactic Cefazolin* Antibiotic Regimen (DRUG), 5-Days Prophylactic Cefazolin* Antibiotic Regimen (DRUG).
Who is sponsoring clinical trial NCT01479283?
This trial is sponsored by McMaster University, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01479283's enrollment target sits among peer trials
602 607th of 2000 higher than 1,393 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03849443 · 604 participants · Early Phase 1
Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery
- NCT05238922 · 604 participants · Phase 1
Study of INCB123667 in Subjects With Advanced Solid Tumors
- NCT06040541 · 604 participants · Phase 1
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia